LabConnect和Bracken集团伙伴在工业需求不断增长的情况下扩大放射药物服务。 LabConnect and The Bracken Group partner to expand radiopharmaceutical services amid rising industry demand.

LabConnect与Bracken集团合作,扩大其放射药品支持服务,以应对不断增长的工业需求,以15%至20%的年增长率刺激该领域的工业需求。 LabConnect has partnered with The Bracken Group to expand its radiopharmaceutical support services, responding to growing industry demand fueled by 15% to 20% annual growth in the field. 合作加强了抽样处理、后勤和科学监督方面的能力,使生物制药和生物技术客户能够制定有针对性的诊断和疗法。 The collaboration enhances capabilities in sample processing, logistics, and scientific oversight for biopharmaceutical and biotech clients developing targeted diagnostics and therapies. 布拉肯集团在放射性药物开发,监管战略和商业化方面拥有专业知识,支持LabConnect的使命提供综合,高质量的临床试验服务. The Bracken Group brings expertise in radiopharmaceutical development, regulatory strategy, and commercialization, supporting LabConnect’s mission to provide integrated, high-quality clinical trial services. 该伙伴关系旨在加强复杂、受监管的试验的交付,同时推动放射性制药业的创新。 The partnership aims to strengthen the delivery of complex, regulated trials while advancing innovation in radiopharmaceuticals.